SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) traded down 15.4% during mid-day trading on Wednesday. The stock traded as low as $10.51 and last traded at $10.2990. 3,980,290 shares traded hands during mid-day trading, a decline of 49% from the average session volume of 7,797,942 shares. The stock had previously closed at $12.17.
Analyst Ratings Changes
A number of research analysts have weighed in on SLS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $10.00.
SELLAS Life Sciences Group Price Performance
The company has a market cap of $2.02 billion, a PE ratio of -47.45 and a beta of 2.56. The company has a 50-day moving average price of $12.36 and a two-hundred day moving average price of $8.47.
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01).
Institutional Investors Weigh In On SELLAS Life Sciences Group
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nykredit A S acquired a new stake in shares of SELLAS Life Sciences Group during the second quarter worth $27,000. GAMMA Investing LLC boosted its stake in shares of SELLAS Life Sciences Group by 293.2% during the 3rd quarter. GAMMA Investing LLC now owns 2,186 shares of the company’s stock worth $27,000 after buying an additional 1,630 shares during the last quarter. California State Teachers Retirement System increased its holdings in SELLAS Life Sciences Group by 22.4% during the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after buying an additional 1,709 shares during the last quarter. Wealthfront Advisers LLC acquired a new stake in shares of SELLAS Life Sciences Group in the first quarter valued at approximately $48,000. Finally, Principal Financial Group Inc. acquired a new position in shares of SELLAS Life Sciences Group in the first quarter valued at approximately $53,000. Institutional investors and hedge funds own 17.38% of the company’s stock.
SELLAS Life Sciences Group Company Profile
SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. The company’s research and development programs are centered on treatments designed to stimulate or restore the immune system’s ability to recognize and attack cancer cells, as well as targeted therapies for hematologic malignancies.
SELLAS’ lead product candidate is galinpepimut-S (GPS), a multi-peptide immunotherapeutic targeting Wilms’ tumor 1 (WT1), a protein expressed in multiple types of cancer.
Featured Stories
- Five stocks we like better than SELLAS Life Sciences Group
- Welltower’s Strong Earnings Couldn’t Stop the Sell-Off—What’s Missing?
- Sherwin-Williams Remains Evergreen in a Frozen Housing Market
- Palantir’s Q3 Bar Is Higher Than It Looks: 3 Numbers to Watch
- Johnson Controls Beats the Heat in AI Data Centers
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
